Lipid 23 is an ionizable cationic amino lipid (pKa = 5.7) that has been used with other lipids in the formulation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing lipid 23 and encapsulating an mRNA reporter accumulate specifically in the mouse liver.

SMD-3040 is a potent and selective SMARCA2 degrader with DC50 of 12 nM and demonstrates an excellent degradation selectivity for SMARCA2 over SMARCA4. SMD-3040 achieves strong tumor growth inhibition in two SMARCA4-deficient xenograft models at well-tolerated dose schedules.

OC2-K3-E10 is an ionizable cationic lipid (pKa = 6.8).1 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA for genome editing in transgenic mice.

CL4F8-6 is an ionizable cationic lipid (pKa = 6.14) that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 Intravenous administration of LNPs containing CL4F8-6 and encapsulating an mRNA reporter accumulate specifically in the mouse liver. LNPs containing CL4F8-6 and encapsulating mRNA encoding the Cas9 nuclease (mCas9) and single-guide RNA (sgRNA) targeting Ttr (sgTtr), the gene encoding transthyretin, have been used to induce CRISPR-mediated gene knockdown in mice resulting in a reduction of serum levels of TTR.

AOH1996 is a proliferating cell nuclear antigen (PCNA) inhibitor. AOH1996 enhances PCNA and RPB1 interaction and interferes with TRC resolution and induces DNA double-stranded breaks in a transcription dependent manner. AOH1996 almost completely inhibits the growth of xenograft tumors without causing any discernible toxicity to experimental animals.AOH1996 has superior metabolic stability as compared to the AOH1160 parent molecule. 

1O14 is an ionizable cationic lipid that has been used in combination with other lipids in the formation of lipid nanoparticles (LNPs).1 1O14-containing LNPs have been used for the delivery of IL-1β siRNA to induce gene silencing and hepatoprotective effects in a mouse model of acute liver injury induced by LPS and galactosamine (GalN).

Lipid catechol is a lipid that contains an α-aminophosphonate group, two 14-carbon acyl chains, and a catechol ring that forms a covalent bond with boronic acid-containing compounds to form lipid prodrug nanoassemblies (LPNA).1 LPNAs composed of lipid catechol conjugated to phenylboronic acid-modified ciprofloxacin (CIP-PBA) inhibit the formation of, and disrupt preformed, S. aureus biofilms and eradicate staphylococci in a mouse model of peritoneal S. aureus infection. LPNAs composed of lipid catechol conjugated to bortezomib (BTZ) reduce tumor growth and increase survival in a 4T1 murine mammary carcinoma model.

ALC-0366 (III-45) is an ionizable cationic lipid (pKa = 6.25).It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA in vivo.1,2,3 LNPs containing lipid III-45 and encapsulating a luciferase mRNA reporter accumulate in liver and adipose tissue in mice.LNPs containing lipid III-45 have been used to deliver an mRNA sequence encoding an antibody targeting the tumor-associated antigen and tight junction integral protein claudin-18 isoform 2 (claudin-18.2) to mice and reduce tumor volume in an MDA-MB-231 mouse xenograft model.

SC9 is an uncompetitive inhibitor of WT dynamin-related protein 1 (Drp1) with IC50 of 270 nM. SC9 completely prevents the LPS-induced decline in cells with fused mitochondria.

SM-102 N-oxide is potential impurity in commercial preparations of SM-102.

DIM7S is a sugar-alcohol-derived ionizable lipid with mannitol as the precursor. DIM7S LNP is 10-fold, 30-fold, 20-fold, 4-fold and 3-fold superior in mRNA delivery than Lipo 3K, Electro, ALC-0315, MC3 and SM-102, respectively. DIM7S LNP enables effective CD40 mRNA delivery into human peripheral blood monocyte-derived DCs without obvious cytotoxicity.

Recilisib (ON01210, EX-RAD) is a radioprotectant that activates the activity of AKT and PI3K in cells. It has been studied as prophylactic (use prior to radiation exposure) and therapeutic (after exposure to radiation) drug.

way-119064 is a highly potent GSK-3β inhibitor with an IC50 value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease[1].

SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.

Stafia-1 is the first STAT5a inhibitor that inhibits STAT5a (IC50=22.2 μM, Ki=10.9 μM) with at least 9‐fold selectivity over STAT5b and higher selectivity against other STAT family members.

ATR inhibitor 1 is a ATR inhibitor extracted from patent WO2015187451A1, compound I-l, has a Ki value below 1 µΜ[1].

5-Chloro-2'-deoxyuridine, a thymine analog, is to study the potential of hypochlorous acid damage to DNA and DNA precursors.

Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).

ATM Inhibitor-5 [formula (1)] is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1)[1].

Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively[1]. Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases[2].

Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors.